| | | 上海阿拉丁生化科技股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、《上海证券交易所科创板股票上市规则》和《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》及《上海阿拉丁生化科技股份有限公司募 集资金管理制度》（以下简称"《募集资金管理制度》"）等规定，上海阿拉丁生化 科技股份有限公司（以下简称"公司"）董事会编制了截至 2023 年 6 月 30 日的募 集资金存放与实际使用情况的专项报告，具体如下： 一、 募集资金基本情况 1、首次公开发行股票 经上海证券交易所科创板上市委员会 2020 年 8 月 11 日审核同意，并经中国 证券监督管理委员会 2020 年 9 月 7 日《关于同意上海阿拉丁生化科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕2116 号）注册同意，公司 向社会公开发行人民币普通股（A 股）股票 ...

西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2022年度持续督导工作现场检查报告 上海证券交易所： （四）现场检查人员：滕晶、贾喻杰 （五）现场检查内容：公司治理及内部控制，信息披露情况，公司独立性以及 与控股股东、实际控制人及其他关联方资金往来情况，募集资金使用情况、关联交 易、对外担保、重大对外投资情况，公司经营状况等。 （六）现场检查手段：与公司相关董事、高级管理人员进行访谈；查看上市公 司主要经营、管理场所；查阅并收集公司持续督导期间召开的历次三会文件；查阅 并收集上市公司募集资金台账、募集资金使用凭证、募集资金专户银行对账单等资 料；查阅并收集公司建立或更新的有关内控制度文件；查阅上市公司定期报告、临 时报告等信息披露文件；核查公司对外投资的相关资料；检查公司及董监高所做承 诺及履行情况。 二、现场检查的具体事项及意见 1 （一）公司治理和内部控制情况 根据《上海证券交易所上市公司自律监管指引第11号——持续督导》等有关法 律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为上海阿拉丁 生化科技股份有限公司（以下简称"阿拉丁"、"公司"）持续督导阶段的保荐人， 于2023年7 ...

重要内容提示： 投资者可于 2023 年 06 月 05 日(星期一) 至 06 月 09 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 aladdindmb@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布公司 2022 年年度报告及 2023 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计 划于 2023 年 06 月 12 日 上午 09:00-10:00 举行 2022 年度暨 2023 年第一季度 业绩说明会，就投资者关心的问题进行交流。 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-020 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何 ...

2023 年第一季度报告 证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 | | | --- | --- | --- | --- | | | | 同期增减变动幅 | | | | | 度(%) | | | 营业收入 | | 86,543,299.85 | -5.93% | | 归属于上市公司股东的净利润 | | 17,251,791.95 | -44.38% | ...

Financial Performance - The company's operating revenue for 2022 was CNY 378,104,008.92, representing a year-on-year increase of 31.44% compared to CNY 287,661,274.91 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 92,331,491.84, a slight increase of 3.32% from CNY 89,360,811.30 in 2021[20]. - The net cash flow from operating activities decreased significantly by 388.41%, resulting in a net outflow of CNY 43,261,325.55, compared to a positive cash flow of CNY 15,000,074.03 in 2021[20][22]. - The total assets at the end of 2022 reached CNY 1,476,476,729.30, marking a substantial increase of 58.40% from CNY 932,104,036.16 at the end of 2021[20]. - The basic earnings per share for 2022 was CNY 0.65, down 26.97% from CNY 0.89 in 2021[21]. - The total net assets attributable to shareholders increased by 13.56% to CNY 974,721,715.97 at the end of 2022, compared to CNY 858,317,915.63 at the end of 2021[20]. - The company's comprehensive gross profit margin for 2022 was 58.65%, indicating a strong profitability position despite potential future competition[71]. - The company's inventory turnover rate was 0.56 times, which is below the industry average, indicating slower inventory movement and potential financial risks[72]. Research and Development - Research and development expenses accounted for 10.30% of operating revenue in 2022, an increase of 2.42 percentage points from 7.88% in 2021[21]. - The company applied for 5 new patents during the reporting period, including 3 invention patents and 2 utility model patents[31]. - Total R&D investment reached approximately ¥38.93 million, a 71.79% increase compared to the previous year, accounting for 10.30% of operating income[49]. - The number of R&D personnel increased to 171, up from 119 in the previous year, indicating a growth rate of approximately 43.7%[54]. - The company has developed over 3,200 analytical methods, enhancing its quality control capabilities and product performance characterization[57]. - The company is committed to enhancing its R&D capabilities and optimizing product structure to maintain and improve its industry position[117]. Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management to ensure orderly management[121]. - The company has not reported any significant changes in its independence or ability to operate autonomously from its controlling shareholders[121]. - The company has established specialized committees, including audit, nomination, remuneration, and strategic committees, to enhance governance[151]. - The company has maintained transparency in information disclosure, ensuring timely and accurate communication with investors[184]. - The company has received a standard unqualified opinion in its internal control audit report for the year 2022[181]. Market Position and Strategy - The company operates in four main fields: high-end chemistry, life sciences, analytical chromatography, and materials science[32]. - The company is one of the most comprehensive manufacturers of research reagents in China, focusing on import substitution and brand development[41]. - The market for high-end reagents in China remains significantly underserved, indicating potential growth opportunities for the company[38]. - The company has established a fully-owned subsidiary, Aladdin Technology Pte. Ltd., to explore overseas market expansion[113]. - The company plans to expand its product line in four key areas: high-end chemicals, life sciences, analytical chromatography, and materials science[117]. Environmental Compliance - The company has complied with all environmental regulations, with no penalties received during the reporting period[183]. - The company has implemented a comprehensive environmental monitoring plan, ensuring compliance with industry standards for wastewater, waste gas, and noise detection[193]. - The company has established a dedicated hazardous waste warehouse and ensures compliance with hazardous waste disposal regulations through qualified third-party services[198]. - The company reported a total of 5.933 tons of waste from scrapped pharmaceuticals generated during the year, with no remaining inventory at year-end[188]. Employee Welfare and Compensation - The company actively promotes employee welfare, including social insurance and health check-ups, to retain talent[160]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.3769 million RMB[143]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 2.1525 million RMB[143]. - The company has established a performance evaluation mechanism for senior management, linking compensation to the achievement of operational and profitability goals[178]. Future Outlook - The company provided guidance for 2023, projecting revenue growth of 10% to 1.32 billion, driven by new product launches and market expansion[134]. - The company plans to implement cost-cutting measures aimed at improving operating margins by 5%[136]. - The company is exploring partnerships with tech firms to leverage AI technologies, aiming to integrate these into its product suite by 2024[134].

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 接待投资者调研活动记录 一、机构调研情况 调研时间：2022 年 4 月 01 日-2022 年 4 月 30 日 调研形式：线上交流 参与交流来访的机构投资者： 浙商证券、光大证券、富国基金、汇添富基金、中欧基金、嘉实基金、中信证券、 中泰证券、华创证券、博时基金、爱建证券、安信基金、宝盈基金、碧云资本、 博远基金、财通基金、楚恒资产、淳厚基金、鼎锋资产、东方红资管、东海自营、 东吴自营、方正富邦、歌汝私募、格林基金、亘曦资产、工银安盛、工银瑞信、 固禾资产、观合资产、光证资管、国君自营、国联安基金、国盛证券、国寿安保、 国泰基金、国投瑞银基金、灏霁投资、鹤禧投资、横琴人寿、红筹投资、泓澄资 本、华泰柏瑞、华泰证券自营、华夏基金、汇华基金、汇华理财、惠升基金、坚 果资本、建信养老、金鹰基金、进化论资管、泾溪投资、九泰基金、聚鸣投资、 凯石基金、理成资产、弥远投资、名禹资产、摩根华鑫、鹏华基金、平安基金、 平安寿险、平安养老、前海开源、趣时资产、人保资产、融通基金、上海勤辰、 盛世知己、太平养 ...

Financial Performance - The net profit attributable to shareholders for the first half of 2022 was RMB 56,175,769.54, representing a growth of 36.05% compared to the same period last year[19]. - The company's operating revenue for the first half of 2022 was ¥177,339,773.92, representing a growth of 36.17% compared to the same period last year[22]. - Net profit attributable to shareholders for the same period was ¥50,258,545.94, an increase of 21.72% year-over-year[22]. - Basic earnings per share decreased by 12.20% to ¥0.36, while diluted earnings per share fell by 14.63% to ¥0.35[20]. - The net profit excluding non-recurring gains and losses was ¥45,876,405.38, reflecting a 15.29% increase year-over-year[22]. - The company reported a total revenue of 14,185 million RMB for the first half of 2022, with a net profit of 1,680.66 million RMB, representing a year-on-year increase of 2,917.89 million RMB[49]. Research and Development - The company's R&D investment as a percentage of operating revenue increased by 2.48 percentage points to 9.47%[20]. - The company achieved a significant increase in R&D investment, totaling ¥16,802,484.58, representing a year-on-year growth of 84.55%[42]. - R&D expenses accounted for 9.47% of total revenue, an increase of 2.48 percentage points compared to the previous year[42]. - The number of R&D personnel increased to 131, accounting for 26.36% of the total workforce, up from 24.18% in the previous year[51]. - The total compensation for R&D personnel reached 1,104.68 million RMB, with an average salary of 8.43 million RMB, compared to 5.99 million RMB in the previous year[51]. - The R&D team includes 3 PhD holders, 53 master's degree holders, and 59 bachelor's degree holders, showcasing a diverse educational background[51]. Risk Management - The company has detailed various risks and countermeasures in the report, emphasizing the importance of risk management[4]. - The company faces risks related to core technology leakage and the retention of key technical personnel, which are critical for maintaining competitive advantage[62][63]. - The company’s gross and net profit margins are currently high, but there is a risk of decline due to increased competition and potential raw material price hikes[69]. - The company is exposed to macroeconomic risks that could affect demand and necessitate adjustments in operational strategies[72]. Corporate Governance - The company has conducted board meetings to review and approve various reports and proposals, including the annual financial budget[90]. - The company emphasizes the importance of accurate and complete financial reporting, with management taking responsibility for the report's integrity[5]. - The company has committed to using raised funds in accordance with the specified projects, with detailed usage reports available[151]. - The company will manage raised funds strictly according to its usage and management system, ensuring efficient use to enhance profitability[115]. Environmental Responsibility - The company has not experienced any significant environmental incidents and adheres to strict environmental protection standards[94]. - The company has implemented effective waste management practices, including the classification and proper disposal of hazardous waste[95]. - The company emphasizes energy efficiency and has established measures to reduce energy consumption and improve usage rates[94]. - The company has conducted board meetings to review and approve various reports and proposals, including the annual financial budget[90]. Shareholder Commitments - The company has made commitments related to share restrictions for major shareholders and management personnel, ensuring compliance with lock-up periods[101]. - Major shareholders, including Xu Jiuzhen and Zhao Liping, committed to not transferring shares for 12 months post-IPO[105]. - The company has established a plan for gradual share reduction post-lock-up, adhering to regulatory requirements[108]. - The company will complete the distribution of dividends within two months after the shareholders' meeting approves the profit distribution plan[123]. Financial Position - The total assets at the end of the reporting period were ¥1,368,632,881.73, a significant increase of 46.83% from the previous year[22]. - Cash and cash equivalents increased by 86.90% to approximately 652.61 million, representing 47.68% of total assets compared to 37.46% last year[83]. - Accounts receivable rose by 87.74% to approximately 44.59 million, accounting for 3.26% of total assets, up from 2.55% last year[83]. - The company’s asset-liability ratio increased to 32.33% from 7.92%, a change of 24.41%[189]. Market Strategy - The company aims to expand its product variety by over 30,000 new items, enhancing supply chain capabilities across procurement, production, and sales[21]. - The company is actively expanding its e-commerce platform to enhance sales and customer experience in the scientific services sector[35]. - The company is focusing on the development of high-purity reagents and specialized reagents to meet the growing demands of emerging industries[34]. - The company is committed to expanding its market presence through innovative product development and strategic investments in research and technology[46].

Financial Performance - The company's operating revenue for Q1 2022 was ¥91,998,831.14, representing a year-on-year increase of 46.69%[5] - The net profit attributable to shareholders was ¥31,019,842.19, reflecting a growth of 54.82% compared to the same period last year[5] - Total operating revenue for Q1 2022 reached ¥91,998,831.14, a 46.6% increase from ¥62,717,903.12 in Q1 2021[26] - Net profit attributable to shareholders for Q1 2022 was ¥31,019,842.19, up 54.8% from ¥20,036,519.25 in Q1 2021[20] - Operating profit for Q1 2022 was ¥32,628,603.52, compared to ¥26,241,332.39 in Q1 2021, reflecting a growth of 24.5%[19] - The total comprehensive income for Q1 2022 was ¥31,020,402.52, compared to ¥20,364,883.08 in Q1 2021, indicating a growth of 52.5%[27] - The company reported a gross profit margin of approximately 36.0% in Q1 2022, compared to 42.0% in Q1 2021[19] - Basic and diluted earnings per share for Q1 2022 were both ¥0.30, an increase from ¥0.20 in Q1 2021[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,348,910,827.05, up 44.72% from the end of the previous year[6] - Total assets as of Q1 2022 amounted to ¥1,348,910,827.05, significantly higher than ¥932,104,036.16 in the previous year[17] - The total assets increased to ¥1,493,008,496.31 in Q1 2022, compared to ¥1,075,395,582.11 in Q1 2021, reflecting a growth of 38.8%[26] - Total liabilities for Q1 2022 were ¥329,967,338.77, compared to ¥73,786,120.53 in Q1 2021, indicating a substantial increase[17] - The total liabilities increased to 474,952,251.30 RMB from 217,577,764.50 RMB, indicating a significant rise in the company's debt levels[25] Cash Flow - The net cash flow from operating activities was negative at -¥14,075,845.34, indicating a significant increase in cash outflows[6] - Cash flow from operating activities in Q1 2022 was ¥93,112,817.01, an increase from ¥69,946,365.58 in Q1 2021[21] - The net cash flow from operating activities was -14,075,845.34 RMB, compared to -1,669,224.00 RMB in the previous year, indicating a significant decline in operational cash flow[22] - The cash inflow from financing activities was 374,692,622.18 RMB, a notable improvement compared to -1,288,000.58 RMB in the previous year[23] - The cash outflow for investment activities was -6,863,342.14 RMB, compared to a positive cash flow of 1,408,196.59 RMB in the previous year, indicating a shift in investment strategy[22] Shareholder Information - The top shareholder, Xu Jiuzhen, holds 28,000,000 shares, representing 27.74% of total shares[12] - The second-largest shareholder, Zhao Liping, owns 15,000,000 shares, accounting for 14.86% of total shares[12] - The company has not reported any significant changes in shareholder relationships or actions among the top ten shareholders[13] Research and Development - Research and development expenses totaled ¥7,433,041.91, which is 8.08% of operating revenue, an increase of 1.72 percentage points year-on-year[6] - Research and development expenses for Q1 2022 totaled ¥7,433,041.91, up from ¥3,991,147.69 in Q1 2021, marking an increase of 86.5%[19] - Research and development expenses increased to ¥7,435,012.10 in Q1 2022, up 84.5% from ¥4,030,108.55 in Q1 2021[26] Inventory and Receivables - Accounts receivable increased to ¥33,752,757.05 from ¥23,751,799.49, reflecting a growth of about 42% year-over-year[15] - The company’s accounts receivable rose to 33,752,757.05 RMB from 23,751,799.49 RMB, representing an increase of approximately 42.2%[24] - Inventory levels rose to ¥222,444,532.30 compared to ¥180,994,917.11, indicating an increase of approximately 23%[15] - The company’s inventory increased to 221,444,532.30 RMB from 180,994,917.11 RMB, reflecting a 22.4% rise in stock levels[24] Government Subsidies and Other Income - The company received government subsidies amounting to ¥6,393,774.27, significantly boosting other income[9] Market and Future Outlook - The company has not disclosed any new product developments or technological advancements during the reporting period[14] - There are no significant mergers or acquisitions reported in the current quarter[14] - The company has not provided specific future guidance or market expansion strategies in the current report[14]

Financial Performance - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares, totaling 40,373,360.00 RMB, which represents 45.18% of the net profit attributable to shareholders for 2021[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 287,661,274.91, representing a year-on-year increase of 22.82% compared to CNY 234,220,217.66 in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 89,360,811.30, which is a 20.06% increase from CNY 74,432,146.09 in 2020[22]. - The basic earnings per share for 2021 was CNY 0.89, a decrease of 4.30% compared to CNY 0.93 in 2020[23]. - The diluted earnings per share for 2021 was also CNY 0.89, consistent with the basic earnings per share[23]. - The gross profit margin for 2021 was 62.26%, while the net profit margin was 31.06%, indicating a stable profitability level[83]. - The company's total operating revenue increased compared to the previous year, with significant growth in sales leading to a rise in total costs[101]. - The company reported a significant increase in sales expenses, which rose by 102.53% to 19,888.51 million, primarily due to increased personnel costs[107]. - The company reported a revenue increase of 15% year-over-year, reaching $1.5 billion in Q3 2023[138]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in Q3 2023[140]. Research and Development - Research and development expenses accounted for 7.88% of operating revenue in 2021, an increase of 1.18 percentage points from 6.70% in 2020[23]. - The total R&D investment for the year was approximately ¥22.66 million, representing a 44.48% increase compared to the previous year, with R&D investment accounting for 7.88% of operating income[59]. - The company applied for 7 new patents during the reporting period, including 3 domestic invention patents, 2 utility model patents, and 2 design patents[33]. - The company is focusing on differentiated, refined, and series development in response to diverse user needs, emphasizing the importance of continuous R&D investment and technological upgrades[52]. - The company is actively developing new reagent varieties through continuous R&D and process development, with a clear trend towards domestic production of research reagents[51]. - The company is investing $200 million in R&D for new technologies aimed at enhancing product features and user experience[138]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficiency[140]. Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and senior management to ensure orderly management[125]. - The company has established a comprehensive governance structure, ensuring compliance with laws and regulations, and has maintained a transparent information disclosure process to protect shareholder rights[196]. - The company has not faced any penalties from securities regulatory authorities in the past three years[148]. - The company has established rules for the bondholders' meeting to ensure effective communication and governance[129]. Market Position and Strategy - The company aims to build a diverse library of recombinant proteins and antibodies to meet the varied needs of its customers in the life sciences sector[34]. - The company is recognized as one of the most comprehensive domestic manufacturers of research reagents, achieving a high reputation in the industry through its "Aladdin" brand and import substitution strategy[48]. - The company focuses on developing its own "Aladdin" brand for research reagents and "Chip Silicon Valley" brand for laboratory consumables, moving away from foreign brand agency strategies[82]. - The company is exploring potential acquisitions to strengthen its market position, with a focus on complementary technologies[138]. - The company is focusing on expanding its market presence through strategic initiatives and potential mergers and acquisitions[129]. Financial Management - The company has established a comprehensive internal control system and has not reported any significant deficiencies during the reporting period[179]. - The internal control audit report received a standard unqualified opinion, indicating effective internal controls[180]. - The company has committed to using temporarily idle raised funds for cash management, optimizing financial resources[150]. - The company has conducted feasibility analysis reports regarding the use of raised funds from previous financing activities[129]. Social Responsibility and Sustainability - The company actively participates in social responsibility initiatives, including donations for public welfare projects, with a specific contribution of 20,000 RMB for a charity event[193]. - The company has established an environmental management system and successfully completed ISO 14001 certification during the reporting period[190]. - The company has implemented a waste management system, including the proper handling of hazardous waste and promoting recycling among employees[189]. - The company is classified as a low energy consumption enterprise, primarily using electricity and water, and has implemented measures to reduce energy consumption[187]. Employee and Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 572.46 million RMB[147]. - The total remuneration for core technical personnel at the end of the reporting period was 215.62 million RMB[147]. - The company has maintained a stable number of shares held by key executives, with no increase or decrease reported[133]. - The company has developed a training program focusing on enhancing R&D capabilities and includes both internal and external training initiatives[163].

2021 年第三季度报告 证券代码：688179 证券简称：阿拉丁 上海阿拉丁生化科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 2 / 12 2021 年第三季度报告 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 12 单位：元 币种：人民币 项目 本报告期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 年初至报告 期末比上年 同期增减变 动幅度(%) 营业收入 67,337,429.31 -1.68% 197,574,370.59 23.53% 归属于上市公司股东的净利润 18,246,599.64 -24.01% 59,536,859 ...